Please login to the form below

Not currently logged in
Email:
Password:

Illumina expands board of directors

John Thompson brings experience from IBM and Microsoft

Illumina John ThompsonSan Diego, US-based Illumina has appointed John Thompson to its board of directors.

Thompson will join the DNA sequencing specialist in May this year, bringing over 30 years of sales and management experience in the technology sector to the position.

He is currently chairman of the board at Microsoft, and served as chief executive officer of IT infrastructure service Virtual Instruments between 2010 and 2016.

Prior to this, Thompson served as both chairman and chief executive officer of Symantec, and also brings experience from IBM having served as general manager of IBM Americas.

Francis de Souza, president and chief executive of Illumina, said: “John brings a great breadth of knowledge and experience in the public and private sectors having served in such a wide range of leadership and advisory roles.

“His wealth of technology expertise will help us continue to grow and scale our business in the years to come.”

21st February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics